Description
Beyond starting a statin
Most clinicians manage lipids competently up to the point where a statin at maximum tolerated dose has not achieved target. After that the decisions become genuinely specialist — which agent next, whether the residual risk is lipid-driven at all, when a lipoprotein(a) measurement changes anything, and which patients need a familial hypercholesterolaemia work-up rather than another dose increase.
These 349 pages begin where general practice guidance ends.
Distinct from the prevention collection
The Academy prevention track covers lipids as one risk factor among several, at the depth a risk clinic needs. This volume is the subspecialty text, taken by members who run lipid clinics or who want the pharmacology properly rather than operationally. Members frequently take both; they are not substitutes.
The eighteen chapters
Lipoprotein biology at the level that actually informs prescribing. Measurement, including when a fasting sample matters and when apoB is the better number. Statin intolerance, distinguishing genuine myopathy from the nocebo effect that trials repeatedly demonstrate. Ezetimibe, PCSK9 inhibition, bempedoic acid and inclisiran, sequenced by evidence rather than novelty. Hypertriglyceridaemia and pancreatitis risk. Lipoprotein(a) and what can currently be done about it. Familial hypercholesterolaemia, including cascade screening. Lipids in chronic kidney disease, diabetes and pregnancy.
Academy placement
Prevention track, advanced tier. Also recommended to members in endocrinology and nephrology, who manage a large share of complex dyslipidaemia without a cardiology referral.
PDF, 349 pages, lifetime access from CardiologyBooks.com.
Reviews
There are no reviews yet.